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Clozapine is one of the atypical antipsychotics and is fre-
quently prescribed to patients with treatment-resistant 
schizophrenia. The most severe side effect of this medication 
is agranulocytosis, and the prevalence of developing this 
condition ranges between 0.7-4.1%.[1,2] Febrile neutropenia 
attributed to clozapine use occurs in 0.06% of patients.[3] 
There have been case reports that have demonstrated that 
atypical antipsychotics other than clozapine may also in-
duce agranulocytosis.[4,5] In this case report, we present a pa-
tient that developed febrile neutropenia and cellulitis that 
was successfully treated 20 weeks after starting clozapine.
Case Report
A 61-year-old male that had been taking 100 mg of clozap-
ine daily for the past 20 weeks presented with complaints 
of a right leg rash and fever for three days. His past medical 
history was notable for a diagnosis of schizophrenia when 
he was approximately 40 years-old. His symptoms of schizo-
phrenia had not been successfully treated with olanzapine, 
quetiapine, and amisulpride, and so he was started on clo-
zapine. However, he was advised to discontinue the drug 
once he developed neutropenia 19 weeks into treatment. 
However, the patient resumed taking the clozapine and de-
veloped a fever and a leg rash four days after he was diag-
nosed with neutropenia. Neither the patient nor his family 
had a history of blood dyscrasias. On physical examination 
his temperature was 38.6˚C, his blood pressure was 120/70 
mmHg, and his pulse was 78 bpm. His heart and lungs were 
within normal limits on auscultation. His right leg however 
was warm to the touch (Figure 1). His laboratory testing re-
vealed a white blood cell (WBC) count of 300/mm³, neutro-
phil count of 0/mm³, platelet (PLT) count of 186,000/mm³, 
hemoglobin (Hb) of 11.6 g/dL, glucose of 111 mg/dL, urea 
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ÖZET
Klozapin atipik antipsikotik ilaçlardan biridir ve sıklıkla tedaviye di-
rençli şizofereni olgularında kullanılmaktadır. Kullanımını sınırlayan 
en önemli yan etkisi ölümcül olabilen agranülositozdur. Bu yazıda, 100 
mg/gün klozapin tedavisinin 20. haftasında nötropenik ateş ve selülit 
gelişen olgu sunuldu.
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of 60 mg/dL, creatinine of 1.3 mg/dL, alanine transaminase 
(ALT) of 13 IU/L, aspartate aminotransferase (AST) of 22 IU/L, 
Na of 137 mmol/L, K of 4.3 mmol/L, and an albumin of 3.6 
g/dL. Atypical cells were not observed on peripheral blood 
smear.
According to these findings, we diagnosed the patient with 
febrile neutropenia and cellulitis. Clozapine treatment was 
immediately stopped and the patient was admitted into 
contact isolation. His MASCC (Multinational Association for 
Supportive Care in Cancer) score was 19 and his temperature 
was 38.6˚C and so blood, throat, and urine cultures were ob-
tained. We began intravenous meropenem at 3 grams/day. 
Also he was started on subcutaneous granulocyte colony 
stimulating factor (G-CSF) treatments with Filgrastim at 30 
million units/day. All of the cultures were negative for infec-
tion. Lower extremity dopplers were performed via ultraso-
nography and there were no abnormal findings. His fever 
resolved on the third day of admission and his neutrophil 
levels began to increase. Meropenem was stopped after 14 
days, and his laboratory values were within normal limits on 
day 14 (Table 1). The patient was referred to the psychiatry 
clinic so to titrate his antipsychotic medications to treat his 
schizophrenia.
Discussion 
Neutropenia and agranulocytosis resulting from treat-
ment with clozapine usually develops within the first three 
months of clozapine initiation. In the first 18 weeks of start-
ing clozapine, a total blood count should be performed on 
a weekly basis. If the blood counts remain within normal 
limits, then total blood counts may be performed monthly.
[1] Despite all of these precautions, agranulocytosis was ob-
served after taking the drug for 11 years in a case report of a 
patient receiving clozapine treatment.[6] A study conducted 
with 2,404 patients that had been taking clozapine for 18 
weeks reported that 0.9% exhibited neutropenia and 0.7% 
percent developed agranulocytosis. Yet, all of these patients 
fully recovered.[1] In another study of 917 patients that were 
treated with clozapine, it was found that neutropenia oc-
curred in 4.1% of the patients.[2] Between the years of 2005-
Figure 1. Cellulitis of the right leg.
Table 1.  Laboratory values
Date WBC (/mm³) Neutrophil  (/mm³) Hemoglobin (g/dL) Platelet (/mm³)
 (N=4.600-10.200) (N=2.000-6.900) (N=12.2-18.1) (N=14.2000-42.4000)
*14.06.2011 7.800 5.100 12.6 241.000
11.10.2011 6.100 3.100 14.2 217.000
18.10.2011 4.200 1.700 14.6 220.000
**25.10.2011 2.100 100 12.2 193.000
***01.11.2011 400 0 11.6 186.000
02.11.2011 500 0 9.6 195.000
04.11.2011 700 0 9.1 195.000
07.11.2011 1.000 200 7.9 224.000
11.11.2011 1.500 300 7.8 321.000
12.11.2011 2.100 600 8.9 362.000
13.11.2011 3.700 1.200 9.3 320.000
14.11.2011 4.800 2.100 8.5 317.000
*Date that clozapine treatment was initiated. **Date that cessation of clozapine was recommended. ***Date of admission to the hospital 
due to febrile neutropenia with cellulitis.
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2009, side effects due to clozapine use occurred in 21,053 
patients and 0.006% of them were diagnosed with febrile 
neutropenia.[3] We diagnosed this patient with neutropenia 
during the 19th week of treatment. However, his neutrope-
nia worsened due to continuing clozapine against medical 
advice, and the patient presented with febrile neutropenia 
and cellulitis.
The pathophysiology of the development of agranulocy-
tosis during clozapine treatment remains unclear. This side 
effect is not considered to be dose dependent, but it may 
be the result of an idiosyncratic drug reaction.[7,8] There are 
case reports in the literature of patients that developed 
agranulocytosis due to several other antipsychotic medica-
tions.[5,6] Clinical trials and case reports have demonstrated 
that G-CSF is useful in treating clozapine-induced granulo-
cytopenia by stopping agranulocytosis and increasing the 
number of granulocytes and macrophage precursors in the 
bone marrow.[1,2,9] In this case report, the patient responded 
to G-CSF treatment. Because the patient developed neu-
tropenia before the cellulitis was diagnosed, we concluded 
that the neutropenia developed from being treated with 
clozapine and that the cellulitis resulted from the neutro-
penia.
Conclusion
In conclusion, white blood cell counts should be routinely 
performed in patients who are taking clozapine. It is impera-
tive to detect neutropenia in patients taking atypical anti-
psychotics early on so to avoid complications such as cel-
lulitis and to guide clinical treatment in case agranulocytosis 
does develop.
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